ERAS Erasca, Inc. stock chart & analysis
Conviction 49HealthcareScan · Fri, Nov 6, 2026Erasca, Inc. (ERAS) closed at $14.41 (+8.59%) on Nov 6, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 48, RS Rating 99, -40.6% from its 52-week high, +287.4% year to date. Sector: Healthcare · Pharmaceutical Preparations.
Financials as of Tue, Jun 30, 2026 · quarterly.
ERAS technical analysis
Trend
ERAS is in a downtrend: price is below the 50-day, which is below the 200-day moving average. It closed 4.4% below the 50-day ($15.08) and 4.6% below the 200-day ($15.11). The 50-day crossed below the 200-day (a death cross) on the latest session. ADX(14) at 12 points to a weak trend — more range than direction. It meets 3 of 8 trend-template criteria.
Momentum
RSI(14) is 48, in the bearish half of its range. MACD crossed below its signal line one session ago. Its RS Rating of 99 puts its weighted 12-month performance ahead of about 99% of the US market.
Volume and volatility
Volume on the latest session ran 0.6× its 20-day average. It trades about $66.0M a day on average. ATR(14) is $1.10, 7.6% of price — its typical daily range. Bollinger Bands are in a squeeze (19 sessions) — volatility is compressed. Chaikin Money Flow (-0.07) shows distribution.
Key levels
The chart pattern's support is $13.27 and its resistance $16.42. The 52-week range is $2.11 to $24.28; price is 40.6% below the high and 584.6% above the low. The VWAP anchored at the 52-week high is $15.01, above price.
Performance
ERAS returned +0.4% (1 week), -6.8% (1 month), -20.5% (3 months), +42.4% (6 months), +555.0% (1 year), +287.4% (year to date).
About Erasca, Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
Pharmaceutical Preparations · Listed 2021 · 103 employees
Insider activity
SEC Form 4 transactions in ERAS
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Fuchs Charles S. President, R&D · Stock option (right to buy) · 2026-08-10 | Grant | 1.3M | — | 2026-08-10 | 2026-08-12 |
Hambleton Julie Director · Stock option (right to buy) · 2026-06-26 | Grant | 29.89K | — | 2026-06-26 | 2026-06-29 |
Bristol James Arthur Director · Stock option (right to buy) · 2026-06-26 | Grant | 29.89K | — | 2026-06-26 | 2026-06-29 |
LIU JEAN I Director · Stock option (right to buy) · 2026-06-26 | Grant | 29.89K | — | 2026-06-26 | 2026-06-29 |
Casdin Alexander W. Director · Stock option (right to buy) · 2026-06-26 | Grant | 29.89K | — | 2026-06-26 | 2026-06-29 |
Multani Pratik S Director · Stock option (right to buy) · 2026-06-26 | Grant | 29.89K | — | 2026-06-26 | 2026-06-29 |
Start Valerie Denise Harding Director · Stock option (right to buy) · 2026-06-26 | Grant | 29.89K | — | 2026-06-26 | 2026-06-29 |
SEC filings
EDGAR filings in ERAS · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.